IRX-4204 is under clinical development by Io Therapeutics and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer). According to GlobalData, Phase I drugs for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IRX-4204’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IRX-4204 overview
Io Therapeutics overview
Io Therapeutics is a pharmaceutical company that discovers and develops therapeutic compounds. The company develops therapeutic compounds targeting nuclear receptors for cancer, neurodegenerative and auto-immune diseases including multiple sclerosis. Its pipeline products include IRX4204, is an orally available second generation selective RXR agonist against a variety of human cancers in vitro and in animal models including prostate, breast, pancreases and lung and IRX5183, for the treatment of cancer indications. It offers services in areas of medicinal chemistry and pharmacology. Io Therapeutics is headquartered in Santa Ana, California, the US.
For a complete picture of IRX-4204’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
